This Accenture Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Today
6
0
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
- Deutsche Bank analyst Bryan Keane downgraded the rating on Accenture plc (NYSE:ACN) from Buy to Hold, while slashing the price target from $409 to $295. Accenture shares declined 0.2% to close at $306.95 on Tuesday. See how other analysts view this stock.
- Stifel analyst Stephen Willey downgraded Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) from Buy to Hold and lowered the price target from $6 to $1.5. Bolt Biotherapeutics shares slipped …
Full story available on Benzinga.com
Visited 6 times, 1 visit(s) today
